report fiscal adjust ep
consensu expect higher forecast lower-than-
anticip adjust tax rate versu estim account
upsid rel adjust ep forecast
coo fiscal revenu increas year-over-year million
similar consensu expect million slightli
estim million organ growth coopervis
versu estim coopersurg versu
estim modestli exceed forecast similar recent quarter
coopervis organ growth led strong result asia pacif
pro forma basi emea pro forma basi
america growth pro forma basi also exceed estim
addit coopersurg sale paragard iud continu outperform
organ behind compani increas invest advertis
sale support product
slightli estim quarter adjust
gross margin weaker expect bp larg
reflect disrupt transfer manufactur fertil product
costa rica oper ineffici coopersurg
said appear shorter-term disrupt coopersurg adjust
gross margin expect return low rang fiscal
contrast coopervis adjust gross margin bp year-over-year
similar forecast reflect currenc headwind
narrow revenu guidanc million
pro forma organ growth coopervis versu previous
coopersurg versu previous increment
million revenu headwind currenc chang addit increas
adjust ep guidanc
benefit reduc adjust tax rate versu previous
offset higher ep headwind currenc neg
rais adjust ep estim
total debt total asset
organ growth coopervis paragard encourag
compani expect improv fiscal coopervis america organ
growth behind strong new fit data remain comfort coo key account
initi intermediate-term opportun misight myopia control
drive sustain above-market organ growth divis
maintain buy rate rais price target
import pleas read disclosur disclaim page report
report fiscal adjust ep consensu expect higher
forecast lower-than-anticip adjust tax rate versu estim account
upsid rel adjust ep forecast
coo fiscal revenu increas year-over-year million similar consensu
expect million slightli estim million quarter total compani
organ growth roughli estim help off-set slightli greater
revenu headwind currenc chang model
cooper compani incfisc adjust incom statement revenu analysisnorthcoast research thousand except percentag per share gross gross sg sg oper oper net interest incom interest incom incom incom incom tax adjust net adjust net net net wghd com share ep ep revenu growth adjust ep growth analysi revenu compani report northcoast research estim factset
divis standpoint coopervis achiev fiscal organ growth approxim
slightli estim
quarter coopervis result led strength asia pacif pro forma basi emea
pro forma basi aid compani key account initi growth america
pro forma basi also modestli estim note world-wide contact len market
rel stabl quarter roughli year-over-year similar growth last two
quarter coopervis continu gain market share product standpoint coopervis sale
clariti myday daili silicon hydrogel lens remain robust organ revenu
contact lens continu grow organ
coopersurg report fiscal pro forma organ growth exclud carrier screen
non-invasive prenat test filshi clip system prior year revenu estim coopersurg
fiscal organ growth closer forecast quarter sale
paragard iud continu outperform organ behind compani increas invest
advertis sale support product help drive pro forma organ growth coopersurg
offic surgic product notabl growth core offic surgic product held back soft sale
endose hysteroscopi system ahead upcom launch next-gener product aid
coopersurg fiscal addit coopersurg fertil busi post pro forma organ growth
led favor consum sale note coopersurg anniversari decis exit carrier screen
non-invasive prenat test next quarter elimin nois report pro forma growth
coo fiscal adjust oper margin declin bp year-over-year slightli
estim quarter adjust gross margin weaker expect bp
larg reflect disrupt transfer manufactur fertil product costa rica
oper ineffici coopersurg said appear shorter-term disrupt
coopersurg adjust gross margin expect return low rang fiscal contrast
coopervis adjust gross margin bp year-over-year similar forecast
coopervisionquarterli revenu growth analysisnorthcoast research million except daili sihi organ growth daili sihi compani report northcoast research estimatescoopersurg inc organ growth analysissourc compani report northcoast research flat fiscal less anticip invest coopervis distribut center
paragard advertis sale forc expans divis partial off-set strong expens
narrow revenu guidanc million million compani
revis outlook reflect slightli stronger pro forma organ growth coopervis versu
previous coopersurg versu previous increment million revenu
headwind currenc chang addit increas adjust ep guidanc
benefit reduc adjust tax rate versu previous lower interest
expens assumpt million versu million previous offset higher ep headwind
currenc neg versu neg previous previous expect slightli posit
ep impact currenc chang quarter note coo revis guidanc assum exchang
rate modestli lower prior estim in-lin exchang rate day
rais adjust ep estim primarili reflect compani fiscal
perform lower adjust tax rate assumpt
overal deliv larg posit fiscal result includ continu strong organ growth
coopervis paragard encourag compani expect improv fiscal
coopervis america organ growth behind strong new fit data remain comfort coo key account
initi intermediate-term opportun misight myopia control drive sustain above-market
organ growth divis maintain buy rate rais price target
cooper compani guidanc earn earn million coopervis million coopervis pro-forma organ growthup year-over-yearup year-over-year coopersurg million coopersurg pro-forma organ growthup year-over-yearup revenu impact currencyneg millionneg adjust gross marginup modestli year-over-yearup modestli adjust oper marginup modestli year-over-yearup modestli net interest adjust tax adjust adjust ep impact currencyneg compani report northcoast research
cooper compani inc annual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg oper oper net interest interest incom incom incom incom tax minor net incom extra net margin extra extra net net wghd com share ep ep revenu growth adjust ep growth began exclud amort intang adjust ep follow sauflon acquisitionsourc compani report northcoast research estim disclosur
